Mediflorence Medicaments Limited, a active public limited company, was established on 09 February 2012 in New Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24100DL2012PLC231292. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹1.00 M.
It upholds a compliant status. Its leadership includes Sunil Kumar Sharma (Director), Vibhu Sharma (Director), Nishant Agrawal (Director). Past directors included Vibhu Sharma, Shivali Sharma, Sukhvinder Singh. It holds ₹2.00 M open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at B-86, R Block, Dilshad Garden, New Delhi, Delhi, 110095.
U24100DL2012PLC231292
231292
09 February 2012
₹1.00 M
₹1.00 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Mediflorence Medicaments Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunil Kumar Sharma | Director | 09 Feb 2012 | Current |
| Vibhu Sharma | Director | 15 Mar 2021 | Current |
| Nishant Agrawal | Director | 30 Sep 2013 | Current |
| Bijender Kumar Jain | Director | 09 Feb 2012 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 15 Nov 2021 | Past |
| Pramod Abcsdd | Director | 15 Mar 2021 | Past |
| Pramod Abcsdd | Whole-Time Director | 15 Feb 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Mediflorence Medicaments Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 14.61% decrease. The company also saw a substantial improvement in profitability, with a 59.74% increase in profit. The company's net worth Soared by an impressive increase of 10.7%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Mediflorence Medicaments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Nov 2017 | Others | ₹2.00 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Mediflorence Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Mediflorence Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediflorence Medicaments's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Mediflorence Medicaments Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Mediflorence Medicaments Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
The activity Vibhu Sharma was appointed as a Director was appointed as a Director on 15 Mar 2021 & has been associated with this company since 4 years 8 months . was completed.
Progress on A charge with Others amounted to Rs. 2.00 M with Charge ID 100147793 was registered on 08 Nov 2017. was documented.
Progress on Nishant Agrawal was appointed as a Director was appointed as a Director on 30 Sep 2013 & has been associated with this company since 12 years 2 months . was documented.
The activity Sunil Kumar Sharma was appointed as a Director was appointed as a Director on 09 Feb 2012 & has been associated with this company since 13 years 9 months . was completed.
The CIN of Mediflorence Medicaments Limited is U24100DL2012PLC231292.
Mediflorence Medicaments Limited is headquartered at B-86, R Block, Dilshad Garden, New Delhi, Delhi, 110095.
Mediflorence Medicaments Limited was incorporated on 09 February 2012.
The current directors of Mediflorence Medicaments Limited are
The primary industry of Mediflorence Medicaments Limited is Trade.
Mediflorence Medicaments Limited is unlisted.
The authorized capital of Mediflorence Medicaments Limited is ₹1.00 M, and the paid-up capital is ₹1.00 M.
The compliance status of Mediflorence Medicaments Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX